Emergent BioSolutions has entered a strategic financial investment agreement with Swiss Rockets to support infrastructure ...

In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, ...

Emergent BioSolutions (EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring widespread ...

The facility was acquired from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSolutions Inc.

USA-based Emergent BioSolutions (NYSE: EBS) and Swiss vaccines firm Rocketvax have announced an agreement. One part of the ...

Emergent BioSolutions is investing in Swiss biotech Rocketvax, inking a deal designed to fuel the preclinical company’s R&D.

As part of the investment, Emergent would lead U.S. manufacturing and commercialization efforts for four of Rocketvax’s ...

Emergent BioSolutions (EBS) and Rocketvax announced entry into an agreement for Emergent’s strategic financial investment into Swiss Rockets, ...

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

Syngene invests around US$ 50 million to acquire manufacturing facility in US from Emergent: Our Bureau, Bengaluru Tuesday, March 11, 2025, 15:30 Hrs [IST] Syngene International a ...

Syngene International has announced the acquisition of its first biologics manufacturing site in the United States for $36.5 million, marking a significant expansion of its global presence in the ...